Fucosylation is one
of the most prevalent modifications on N- and
O-glycans of glycoproteins, and it plays an important role in various
cellular processes and diseases. Small molecule inhibitors of fucosylation
have shown promise as therapeutic agents for sickle cell disease,
arthritis, and cancer. We describe here the design and synthesis of
a panel of fluorinated l-fucose analogs bearing fluorine
atoms at the C2 and/or C6 positions of l-fucose as metabolic
fucosylation inhibitors. Preliminary study of their effects on cell
proliferation revealed that the 6,6-difluoro-l-fucose (3) and 6,6,6-trifluoro-l-fucose (6)
showed significant inhibitory activity against proliferation of human
colon cancer cells and human umbilical vein endothelial cells. In
contrast, the previously reported 2-deoxy-2-fluoro-l-fucose
(1) had no apparent effects on proliferations of all
the cell lines tested. To understand the mechanism of cell proliferation
inhibition by the fluorinated l-fucose analogs, we performed
chemoenzymatic synthesis of the corresponding GDP-fluorinated l-fucose analogs and tested their inhibitory activities against
the mammalian α1,6-fucosyltransferase (FUT8). Interestingly,
the corresponding GDP derivatives of 6,6-difluoro-l-fucose
(3) and 6,6,6-trifluoro-l-fucose (6), which are the stronger proliferation inhibitors, showed much weaker
inhibitory activity against FUT8 than that of the 2-deoxy-2-fluoro-l-fucose (1). These results suggest that FUT8 is
not the major target of the 6-fluorinated fucose analogs (3 and 6). Instead, other factors, such as the key enzymes
involved in the de novo GDP-fucose biosynthetic pathway
and/or other fucosyltransferases involved in the biosynthesis of tumor-associated
glyco-epitopes are most likely the targets of the fluorinated l-fucose analogs to achieve cell proliferation inhibition. To
our knowledge, this is the first comparative study of various fluorinated l-fucose analogs for suppressing the proliferation of human
cancer and primary endothelial cells required for angiogenesis.